 |
|
 2004 NEWS ARCHIVE |
| |
| METABOLEX RAISES $44
MILLION IN ADDITIONAL PRIVATE FINANCING
|
|
| Edward E. Penhoet,
Ph.D., Chiron Co-Founder, Elected Chairman of the Board |
|
|
| November
30, 2004 |
|
Metabolex, Inc.,
a privately held pharmaceutical firm that discovers and develops
drugs to treat diabetes and related metabolic diseases, today
announced that it has raised $44 million in a private equity
financing led by Alta Partners. Additional new investors in
the round include Venrock Associates, Versant Ventures and
Novo A/S. Previous Metabolex investors participating in this
closing included Bay City Capital, KBC Bank & Insurance
Group, and Birchmere Ventures, along with VantagePoint Venture
Partners. This financing is the third close of the company’s
financing announced in August 2003, bringing the total amount
raised in this round to $75 million... |
|
|
|
|
|
| |
METABOLEX
ANNOUNCES START OF PHASE 2 TRIAL OF ITS NOVEL INSULIN
SENSITIZER,
Metaglidasen |
|
| Drug Well-tolerated
in Phase 1 Study; G.I. Toxicity of Halofenate Not Seen |
|
|
|
| March
2, 2004 |
|
Metabolex, Inc., today
announced the start of its Phase 2 study of its investigational
insulin sensitizer, metaglidasen. The double-blind,
placebo-controlled study will enroll approximately
200 patients with type 2 diabetes who are currently
on insulin, but whose fasting blood-glucose levels
are not well controlled. Researchers at 29 centers
throughout the United States and Mexico will participate
in the study, which is expected to complete in early
2005....
|
|
|
|
|
| |
| METABOLEX APPOINTS DAVID B.
KARPF, M.D. AS CHIEF MEDICAL OFFICER |
|
| February 9, 2004 |
|
Metabolex, Inc.,
a privately held pharmaceutical firm that discovers and develops
drugs to treat diabetes and related metabolic diseases, today
announced the appointment of David B. Karpf, M.D. as chief
medical officer, effective January 30, 2004. Dr. Karpf joins
Metabolex from Geron Corporation, where he served as executive
medical director, clinical and regulatory affairs since 2001.... |
|
|
|
| |
| METABOLEX ANNOUNCES EXTENSION
OF DRUG DISCOVERY COLLABORATION WITH PFIZER FOCUSED ON INSULIN
SECRETION DEFECTS IN DIABETES |
|
| January 21, 2004 |
|
Metabolex, Inc.,
a privately held pharmaceutical firm that discovers and develops
drugs to treat diabetes and related metabolic diseases, today
announced a one-year extension of its research collaboration
with Pfizer Inc. This collaboration, first initiated with
Parke-Davis (since acquired by Pfizer) in December 1998, is
aimed at discovering new drugs that treat patients with type
2 diabetes by counteracting defects in insulin secretion... |
|
|
|
| |
| METABOLEX RAISES $4 MILLION
IN SECOND CLOSE OF PRIVATE FINANCING FOR TOTAL FUNDING OF $31
MILLION |
|
| January 12, 2004 |
|
Metabolex, Inc.,
a privately held pharmaceutical firm that discovers and develops
drugs to treat diabetes and related metabolic diseases, today
announced that it has raised an additional $4 million in a
second close of its recent private equity financing. This
close brings the total raised by Metabolex in this sixth round
of funding to $31 million... |
|
|
|
|
|
